Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Genome sequencing in myelodysplastic syndromes: can molecular mutations predict benefit from hypomethylating agent therapy?

Expert review of hematology - 1 Apr 2015

Lee Eun-Ju, Zeidan Amer M

Abstract excerpt

Evaluation of: Bejar R, Lord A, Stevenson K, et al. TET2 mutations predict response to hypomethylating agents in myelodysplastic syndrome patients. Blood 2014 Oct 23;124(17):2705-12. Patients with myelodysplastic syndromes (MDS) have clinically variable courses even within the same prognostic subgroups. Although hypomethylating agents (HMAs) have been shown to improve outcomes in patients with high-risk MDS, many...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to DNA-Binding Proteins
Share to DNA Methylation
Share to TET2 gene

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Mutation

Share to Myelodysplastic Syndromes

Share to Proto-Oncogene Proteins

Source

Identifiers

PMID: 25697572
DOI: 10.1586/17474086.2015.1016905

Genes

TET2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Genome sequencing in myelodysplastic syndromes: can molecular mutations predict benefit from hypomethylating agent therapy?PMID 25697572Read ↗

Baseline and serial molecular profiling predicts outcomes with hypomethylating agents in myelodysplastic syndromes.Semantic proximity Read ↗

Optimizing hypomethylating agents in myelodysplastic syndromesSemantic proximity Read ↗

Management of higher risk myelodysplastic syndromes after hypomethylating agents failure: are we about to exit the black hole?Semantic proximity Read ↗

Life after hypomethylating agents in myelodysplastic syndrome: new strategies.Semantic proximity Read ↗

The epigenomics revolution in myelodysplasia: a clinico-pathological perspective.Semantic proximity Read ↗

Myelodysplastic Syndromes: A New Decade.Semantic proximity Read ↗

Myelodysplastic syndromes: Updates on Genomic Landscape, Molecular Subtypes, & Targeted Therapies.Semantic proximity Read ↗

Genomic landscape of myelodysplastic/myeloproliferative neoplasm can predict response to hypomethylating agent therapy.Semantic proximity Read ↗

Society of Hematologic Oncology (SOHO) State of the Art Updates and Next Questions: Myelodysplastic Syndromes.Semantic proximity Read ↗

Molecular taxonomy of myelodysplastic syndromes and its clinical implications.Semantic proximity Read ↗

Somatic mutations predict outcomes of hypomethylating therapy in patients with myelodysplastic syndrome.Semantic proximity Read ↗

Landscape of genetic lesions in 944 patients with myelodysplastic syndromes.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.